Aminoglycoside potentiation for treatment of pulmonary bacterial infection
AssigneeEnbiotix, Inc.
InventorsDiane M. JOSEPH-MCCARTHY, Martina I. KOEVA
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and formulations for treating or preventing bacterial infection in the lungs of a subject, including for controlling P. aeruginosa infection and/or colonization in the lungs of a patient having a chronic lung condition, such as cystic fibrosis (CF), non-cystic fibrosis bronchiectasis (non-CFBE), chronic obstructive pulmonary disorder (COPD), among others. In some embodiments, the invention provides methods and formulations for treating mycobacterial infection.
Claims65
A method for controlling bacterial infection and/or colonization in the lungs of a patient, the method comprising administering to the lungs of the patient by inhalation of a formulation comprising an aminoglycoside antibiotic selected from tobramycin and amikacin, and a proton-motive force stimulating metabolite;
- the molar ratio of the aminoglycoside and the metabolite being in the range of from 1:1 to 1:15.
A unit dose formulation for delivery by nebulizer, the formulation comprising in an aqueous solution:
- from 100 to 400 mg of tobramycin, or from 300 to 600 mg of amikacin;
- and
- from about 100 mg to about 500 mg of one or a combination of metabolites selected from fumarate, pyruvate, methylpyruvate, ethylpyruvate, succinate, glucose, and propionate.
The formulation of 57, packaged in ampules of from 2 to 10 ml.
A unit dose formulation for delivery by powder aerosol, the formulation is a fine powder comprising:
- from 75 to 150 mg of tobramycin, or from 100 to 200 mg of amikacin;
- and
- from about 50 mg to about 250 mg of one or a combination of metabolites selected from fumarate, pyruvate, methylpyruvate, ethylpyruvate, succinate, glucose, and propionate.
Dependencies are inferred from the claim text.